Patricia Recordon Pinson

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitors have been recently developed to inhibit NS5A activities and have been approved for the treatment of HCV infection. However the drawback of these direct acting antivirals (DAAs) is the emergence of resistance mutations. The prevalence of such mutations conferring resistance to HCV-NS5A(More)
  • 1